GSA Capital Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

GSA Capital Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$598K	Sell	162,891 -506,677	-76%	-$1.69M	0.04%	874
2026 Q1	$2.06M	Buy	669,568 +643,851	+2,504%	+$2.49M	0.13%	159
2025 Q4	$105K	Buy	+25,717	New	+$127K	0.01%	1526
2025 Q2	–	Sell	-30,153	Closed	-$160K	–	2097
2025 Q1	$160K	Buy	+30,153	New	+$220K	0.01%	1446
2024 Q1	–	Sell	-10,860	Closed	-$107K	–	1924
2023 Q4	$107K	Buy	+10,860	New	+$77.4K	0.01%	1389
2023 Q1	–	Sell	-22,603	Closed	-$174K	–	1873
2022 Q4	$174K	Buy	+22,603	New	+$222K	0.02%	1216

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GSA Capital Partners's RXRX Position: Q2 2026 in Review

GSA Capital Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 76% in Q2 2026, selling an estimated $1.69M and leaving 162,891 shares worth $598K. The position accounts for 0.04% of the portfolio, ranked #874.

GSA Capital Partners first reported a position in RXRX in Q4 2022 and has held it in 6 quarters since. The position peaked at $2.06M in Q1 2026. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

GSA Capital Partners held 162,891 shares of Recursion Pharmaceuticals worth $598K as of Q2 2026.
GSA Capital Partners sold 506,677 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.69M.
Recursion Pharmaceuticals made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #874 holding.
GSA Capital Partners first reported a position in Recursion Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
GSA Capital Partners's Recursion Pharmaceuticals position peaked at $2.06M in Q1 2026.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.